Dr Chee Goh
Consultant Clinical Oncologist
MBChB (Hons) MRCP FRCR MD (Res)
I received my specialist training in oncology in London from 2005 to 2014, working predominantly at the Royal Marsden Hospital, where I have consolidated my knowledge and interest in cancer treatments enabling me to provide the latest and comprehensive clinical care for my patients. During my training, I also undertook a period of research into the genomic changes in cancer and their clinical manifestations, at the Institute of Cancer Research, leading to the award of an MD degree from the University of London. During that time, I worked closely with the National Institute of Health (USA) and many international collaborators for my research. I have been fortunate enough in my training and research period to work with some of the world’s leading scientists/clinicians in the treatment of cancer. I actively recruit into national trials and have an interest in epidemiological aspects of cancers.
My day to day practice involves managing radiotherapy and systemic therapy for patients with breast and urological cancers. Radiotherapy is currently being offered at either our new Redhill site or the St Luke’s Cancer Centre in Guildford.
Some of the principal treatments carried out by Dr Chee Goh at Spire include:
Radiotherapy and systemic therapy for uro-oncological cancers.
MBChB(Hons) / University of Aberdeen Medical School / 2001
Graduated with Honours
MRCP / UK / 2004
Member of the Royal College of Physicians
FRCR / UK / 2009
Fellow of the Royal College of Radiologists
MD(Res) / University of London / 2014
Doctor in Medicine degree from the Institute of Cancer Research
General Medical Council
Fellow of the Royal College of Radiologists (Clinical Oncology)
Member of the Royal College of Physicians, London
Member of British Uro-oncology Group (BUG)
Eeles R*, Goh C*, Castro E, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 2014;11(1):18-31. *joint first authors.
Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur Urol. 2014. pii: S0302-2838(14)01036-7. doi: 10.1016/j.eururo.2014.10.022
Castro E, Goh CL, Olmos D, et al. Correlation of germline BRCA2 mutations with aggressive prostate cancer and outcome. J Clin Oncol 2013; 31(14):1748-57
Goh CL, Saunders EJ, Leongamornlert DA, et al. Clinical implications of a prostate cancer risk SNP profile in an Active Surveillance cohort. BJU Int 2013;111(7):1148-55
Consultant Clinical Oncologist, Royal Surrey County Hospital and East Surrey Hospital.
Outside of medicine, I do actively take part in community activities including being team leader for a group of weekend volunteers to provide a brunch service for a homeless charity in London. As part of that, I have formal training and qualification for food hygiene and handling. I am also a volunteer for a homeless project managed by Lambeth Council. I enjoy sport, in particular football and running.